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Dialkyl or alkyl aryl esters of 1,2-benzenedi-
carboxylic acid, commonly called phtha-
lates, are ubiquitous industrial chemicals
with a wide range of chemical and toxico-
logic characteristics. Phthalates are used 
primarily as plasticizers in ﬂexible polyvinyl
chloride (PVC) products such as blood bags
and children’s toys. Nonpolymeric uses of
phthalates as fixatives, detergents, lubricat-
ing oils, and solvents lead to their inclusion
in numerous and diverse products such as
cosmetics and wood finishes. The wide-
spread use of phthalates results in multiple
human exposure routes (oral, dermal,
inhalation, and intravenous). Phthalates are
lipophilic compounds that appear not to
bioaccumulate (1). Phthalates are rapidly
metabolized to their respective monoesters
and further oxidative products, which are
glucuronidated and excreted through the
urine and feces (1–4).
Animal toxicology of several phthalates
has been studied. Di-(2-ethylhexyl) phtha-
late (DEHP) is a rodent liver carcinogen
through a mechanism thought to involve
peroxisome proliferation (5); however, car-
cinogenicity by this mechanism is unlikely to
be relevant to humans (6,7). Several phtha-
lates, DEHP, dibutyl phthalate (DBP), and
benzyl butyl phthalate (BzBP), are terato-
genic in animals (8–10). DBP is also toxic to
the testes, possibly through its metabolite,
monobutyl phthalate (MBP) (11,12); other
phthalate metabolites, monobenzyl phthalate
(MBzP) and mono-2-ethylhexyl phthalate
(MEHP), are Sertoli cell toxicants and ter-
atogens in animals (13,14). Furthermore,
administration of DBP and DEHP to preg-
nant rats interferes with normal fetal devel-
opment in male offspring (15). Regarding
reproductive and developmental effects,
phthalates vary in potency, with DEHP
being the most potent and DBP and BzBP
roughly an order of magnitude less potent
(8–15).
Based on the varied toxicities of phtha-
lates, internal dose measurements of speciﬁc
phthalates and their monoester metabolites
(16) are important for exposure assessment,
and ultimately for accurate human risk
assessment. Previous methods for assessing
human exposure to phthalates have been
subject to laboratory and sample-collection
contamination problems from these environ-
mentally ubiquitous compounds (17–20).
For this reason, previous measurements of
internal phthalate dose have focused on
highly exposed people (21,22). As the
primary urinary metabolite, phthalate
monoesters are useful biomarkers of speciﬁc
phthalate exposure. 
We report the urinary phthalate
monoester levels for a human reference pop-
ulation using a new, highly selective tech-
nique (23). This analytical approach allows
us to directly measure the individual phtha-
late metabolites responsible for the repro-
ductive and developmental toxicity of
phthalates in animals while avoiding conta-
mination from the ubiquitous parent 
compound. The metabolites measured are
monoethyl phthalate (MEP), MBP, MBzP,
mono-n-octyl phthalate, MEHP, and
mono-3-methyl-5-dimethylhexyl phthalate
(monoisononyl, MINP). Commercially
used di-isononyl phthalate (DINP) is a
technical mixture containing a number of
different isomers; therefore, several metabo-
lite isomers are expected. We chose the
monoester metabolite of one representative
isomer for DINP. Measurement of this sin-
gle isomer may underestimate exposure to
DINP. Current efforts are focused on quan-
tification of additional metabolites of
DINP. 
Subjects
The urine samples for this study were
originally collected from adults during
1988–1994 as part of the Third National
Health and Nutrition Examination Survey
(NHANES III). Randomly selected urine
samples from 289 subjects were analyzed
for phthalate monoesters. Urine samples
were collected at different times throughout
the day and were not first-morning voids.
This sampling of the NHANES III popula-
tion was not designed to be representative
of the U.S. population but rather to serve
as a reference range for a demographically
described group. The population studied
comprised noninstitutionalized adults aged
20–60 years (mean ± SD 37.4 ± 10.6
years). The gender distribution (56%
female) was similar across age groups.
Racial distribution was weighted toward
minority groups (Caucasian 39%, African
American 30%, Mexican American 23%,
and other 8%).
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Articles
Using a novel and highly selective technique, we measured monoester metabolites of seven com-
monly used phthalates in urine samples from a reference population of 289 adult humans. This
analytical approach allowed us to directly measure the individual phthalate metabolites responsi-
ble for the animal reproductive and developmental toxicity while avoiding contamination from
the ubiquitous parent compounds. The monoesters with the highest urinary levels found were
monoethyl phthalate (95th percentile, 3,750 ppb, 2,610 µg/g creatinine), monobutyl phthalate
(95th percentile, 294 ppb, 162 µg/g creatinine), and monobenzyl phthalate (95th percentile, 137
ppb, 92 µg/g creatinine), reﬂecting exposure to diethyl phthalate, dibutyl phthalate, and benzyl
butyl phthalate. Women of reproductive age (20–40 years) were found to have signiﬁcantly high-
er levels of monobutyl phthalate, a reproductive and developmental toxicant in rodents, than
other age/gender groups (p < 0.005). Current scientiﬁc and regulatory attention on phthalates has
focused almost exclusively on health risks from exposure to only two phthalates, di-(2-ethylhexyl)
phthalate and di-isononyl phthalate. Our ﬁndings strongly suggest that health-risk assessments
for phthalate exposure in humans should include diethyl, dibutyl, and benzyl butyl phthalates.
Key words: exposure, glucuronidase, human, metabolism, phthalates, urine. Environ Health
Perspect 108:979–982 (2000). [Online 1 September 2000]
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The method used has been described previ-
ously (23). All samples were spiked with
13C4-labeled phthalate monoesters and 4-
methylumbelliferone glucuronide. The sam-
ples were then treated with a β -glucuronidase
to release the phthalate monoesters from its
conjugated form. Deconjugated urine sam-
ples were extracted twice with Oasis HLB
SPE (Waters Corp., Milford, MA) as
described (23) and resuspended in mobile
phase. Chromatographic separation by
HPLC was followed with tandem mass spec-
trometry on a triple quadrupole instrument
(Finnigan TSQ 7000; Finnigan MAT, San
Jose, CA) using atmospheric pressure chemi-
cal ionization. Retention times as well as par-
ent-fragment ion combinations have been
described previously (23). Levels of 4-methy-
lumbelliferone were monitored as quality
control for the deconjugation step. Urinary
creatinine was measured with an ASTRA
analyzer (Beckman, Brea, CA) based on a
Jaffé rate reaction, in which creatinine reacts
with picrate in an alkaline solution to form a
red creatinine–picrate complex (24). Results
are reported as micrograms phthalate
monoester per gram of urinary creatinine.
Creatinine adjustment is used to correct for
variations in urine volume. Method blanks,
quality control samples (spiked human
urine), and standards were analyzed along
with unknown human urine samples.
This method has been reﬁned to monitor
and eliminate monoester contamination by
excluding the use of phthalate-containing
plastics, prescreening reagents, and labware,
and routinely monitoring method and instru-
ment blanks. Phthalate diesters are often
components of flexible PVC plastics.
Therefore, products containing this polymer
were not used. Although the polypropylene
and glass components used were unlikely to
contain signiﬁcant amounts of phthalates, we
prescreened representative vials, pipette tips,
glassware, and sampling cups for phthalate
monoester contamination. As an additional
precaution, method blanks were analyzed in
parallel with unknown samples. Insigniﬁcant
phthalate monoester levels were found in
blanks (typically < 0.5% of the mean level
found in human samples). A blank contain-
ing > 5 ppb of any analyte resulted in rejec-
tion of all analytical results acquired on that
day and an effort to identify the source of the
contamination. 
One source of contamination that had to
be eliminated was diester lipase activity in the
glucuronidase enzyme preparation (23). We
enzyme-treated artiﬁcial urine samples (25)
with and without spiked phthalate diesters to
determine if the presence of phthalate diesters
would cause an artifactual increase in phtha-
late monoester levels. When samples spiked
with phthalate diesters were incubated with
β -glucuronidase/sulfatase (Helix pomatia, H-
1), signiﬁcant amounts of the corresponding
phthalate monoesters were formed (MEP,
MBP, MBzP, and MEHP). These enzymes,
H. pomatia β -glucuronidase/sulfatase (from
two vendors), were contaminated with an
enzymatic activity that hydrolyzed phthalate
diesters to generate phthalate monoesters;
nonspeciﬁc lipases with this activity are com-
mon (26). Given the abundance of phthalate
diesters in the environment (including the
laboratory), the use of the H. pomatia β -glu-
curonidase/sulfatase should be avoided for
analysis of phthalate monoesters. Escherichia
coli β -glucuronidase (K12; Roche Biomedical,
Indianapolis, IN) has excellent glucuronidase
activity and no measurable lipase activity on
phthalate diesters. Although this enzyme lacks
sulfatase activity, no phthalate conjugates
other than glucuronides have been detected in
human urine (27). For previously published
phthalate monoester measurements, H.
pomatia β -glucuronidase/sulfatase was used;
therefore artifactually high results may be pre-
sent (3,22). 
Results and Discussion
Our study provides an assessment of
human exposure to phthalates. Phthalate
monoester levels in human urine vary wide-
ly (Table 1); urinary creatinine adjustment
reduces this variation somewhat (Table 2).
In this reference population, the phthalate
monoesters with the highest urinary levels
found are MEP (16,200 ppb, 6,790 µg/g
creatinine), MBP (4,670 ppb, 2,760 µg/g
creatinine), and MBzP (1,020 ppb, 540
µg/g creatinine), which reflect exposure to
diethyl phthalate (DEP), DBP, and BzBP.
DEP and DBP are used extensively in
products with volatile components such as
perfumes, nail polishes, and hair sprays,
possibly leading to inhalation and efﬁcient
absorption through the lungs. Dermal
absorption also occurs at a significant rate
for phthalates with short side chains such as
DEP, DBP, and BzBP (28). 
The highest levels of MEHP in this
study (67 ppb, 192 µg/g creatinine) agree
with levels found previously in urine from
occupationally exposed subjects (22). The
median MEHP levels for this general refer-
ence population were 70-fold lower than the
highest values. In urine, the more lipophilic
phthalate monoesters, such as MEHP and
MINP, were generally found at lower levels
than other monoesters. The relatively low
median MEHP and MINP levels suggest
either low exposures to DEHP and DINP,
storage in adipose tissue, or metabolism and
excretion through another pathway. Limited
data suggest that DEHP is partially excreted
in the feces (1); because of similar lipophilic-
ity, DINP may also be excreted fecally.
Further complicating assessment, DINP
consists of a mixture of phthalate isomers
that yield a large number of monoester
metabolites. Only one of these metabolites,
mono-3-methyl-5-dimethylhexyl phthalate,
was measured in urine and was assumed to
be representative of the presence of other
DINP metabolites. In any event, these data
on monoesters indicate that the internal dose
of MEP, MBP, and MBzP is probably much
higher than that of MINP and MEHP.
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Table 1. Total urinary phthalate monoester concentrations (nanograms monoester per milliliter urine).
Percentile
Geometric 
Phthalate Min 5th 25th 50th 75th 95th Max mean
Ethyl < LOD 26.1 119 305 1,110 3,750 16,200 345
Benzyl 1.4 4.2 11.0 21.2 42.2 137 1,020 22.6
Butyl 2.2 6.9 19.4 41.0 82.3 294 4,670 41.5
Cyclohexyl < LOD < LOD < LOD < LOD < LOD 8.6 13.7 0.3
2-Ethylhexyl < LOD < LOD 1.4 2.7 7.0 21.5 66.6 3.5
Isononyl < LOD < LOD < LOD < LOD < LOD 7.3 79.7 1.5
Octyl < LOD < LOD < LOD < LOD < LOD 2.3 30.5 0.6
Abbreviations: LOD, limit of detection; Max, maximum; Min, minimum. LODs for phthalates (ng/mL) are as follows: MEP,
1.0; MBP, 0.6; MBzP, 0.8; monocyclohexyl phthalate, 0.7; MEHP, 1.2; MNP, 0.8; and mono-n-octyl phthalate, 0.9. 
Table 2. Total urinary phthalate monoester concentrations (micrograms monoester per gram urinary
creatinine).
Percentile
Geometric
Phthalate Min 5th 25th 50th 75th 95th Max mean
Ethyl < LOD 30.2 133 280 704 2,610 6,790 345
Benzyl 2.1 5.0 10.8 19.5 36.9 91.9 544 20.2
Butyl 1.6 9.3 19.4 33.4 60.1 162 2,760 36.9
Cyclohexyl < LOD < LOD < LOD < LOD 0.4 1.0 10.3 0.3
2-Ethylhexyl < LOD < LOD 1.3 2.7 5.2 15.2 192 3.0
Isononyl < LOD < LOD < LOD < LOD < LOD 6.8 90.3 1.3
Octyl < LOD < LOD < LOD < LOD < LOD 2.1 27.0 0.5
Abbreviations: LOD, limit of detection; Max, maximum; Min, minimum. Glucuronidation has been hypothesized to
mitigate phthalate monoester toxicity in
rodents (29). To assess the degree of phthalate
monoester conjugation, we analyzed a subset
of 73 samples with and without β -glu-
curonidase treatment. Low urinary levels of
monoester before deglucuronidation suggest
that MBP and MBzP were present predomi-
nately as the glucuronide form. However, a
small portion (5%) of the reference population
had substantially higher percentages of uncon-
jugated MBP than the rest of the population
(67% above the next lowest value). These dif-
ferences in MBP glucuronidation could be
caused by enzymatic saturation due to a large
recent dose of parent diester phthalate.
Arguing against simple saturation, urinary
MBP levels did not correlate with the ratio of
MBP/MBP-glucuronide. Although based on
limited data, this observation underscores the
potential variability in the human metabolism
of phthalate monoesters and thereby variable
monoester exposure and toxicity.
For analytes found in > 75% of subjects
(MEHP, MEP, MBzP, and MBP), we
examined log-transformed creatinine-adjust-
ed levels by analysis of variance models to
assess effects from selected demographic fac-
tors: age (four groups), sex, race (four
groups), socioeconomic status (two groups),
urban/rural residence, and education (two
groups). All comparison cells described con-
tain > 50 people. Signiﬁcant differences in
creatinine-adjusted values between groups
were not caused by differences in urinary
creatinine levels. Because of the large num-
ber of statistical tests performed on our data,
the effects of demographic factors on urinary
phthalate levels should be considered for
generating hypotheses only. 
After adjustment for the effects of other
factors, creatinine-adjusted MEP levels
increased on average by 1.7% (p < 0.02) for
every yearly increase in age; conversely, crea-
tinine-adjusted MBzP levels decreased by
1% (p < 0.04) for the same increase in age.
Subjects who had completed ≤ 12 years of
formal education had higher levels of MBzP
(22 µg/g creatinine) than subjects with more
formal education (16 µg/g creatinine;
p < 0.01). Further statistical testing indicated
that MBP levels in non-Hispanic whites also
differed between the two education groups
(≤ 12 years: 53 µg/g creatinine; > 12 years:
28 µg/g creatinine; p < 0.001), whereas MBP
levels in non-Hispanic blacks and Hispanics
were comparable regardless of education (33
µg/g creatinine). Further statistical testing
also showed that rural females had signifi-
cantly higher urinary levels of MBzP (26
µg/g creatinine) than rural males (14 µg/g
creatinine; p < 0.001), urban females (19
µg/g creatinine; p < 0.02), and urban males
(18 µg/g creatinine; p < 0.02). 
Of concern, women of childbearing age
(20–40 years) had significantly higher uri-
nary levels of MBP (46.9 µg/g creatinine)
than other sex/age groups (31.4 µg/g creati-
nine; p = 0.003). Furthermore, six of the
eight highest MBP levels were found in these
women. Creatinine adjustment did not
account for this effect. Nine of the highest
10 noncreatinine-adjusted values were found
in women of reproductive age. Ten subjects
had urinary MBP > 300 µg/g creatinine,
including three women of reproductive age
with levels > 2,000 µg/g creatinine (Figure
1). A similar analysis for urinary MBzP did
not indicate a difference, but a more detailed
look at the rural women with high levels of
MBzP suggests that rural women of child-
bearing age have higher levels (31.6 µg/g cre-
atinine) than older (41–60 years) rural
women (21.1 µg/g creatinine). The small
study size and nonrepresentative nature of
this sample population limits the applicabili-
ty of these statistical associations. However,
these ﬁndings do indicate the possibility of
signiﬁcant demographic variations in expo-
sure and/or metabolism.
From a public health perspective, these
data provide evidence that phthalate exposure
is both higher and more common than previ-
ously suspected. Exposure data for phthalates
is critically important for human risk assess-
ment, especially among potentially suscepti-
ble populations. Although DEHP and DINP
are produced in the largest quantities, these
reference range data indicate a substantial
internal human dose of DBP, DEP, and
BzBP. MBP and MBzP are of particular con-
cern because of their developmental and
reproductive toxicity in animals (12–15).
Therefore, assessments of health risk from
exposures to phthalates should include expo-
sures to DBP, DEP, and BzBP. 
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Figure 1. Urinary MBP distribution in a human ref-
erence population. The creatinine-adjusted MBP
levels in spot urine samples were plotted for 289
subjects from the Third National Health and
Nutrition Examination Survey (NHANES III). Ten
subjects (predominantly women of reproductive
age) had urinary MBP levels > 300 µg/g creatinine
(312, 433, 652, 926, 956, 962, 1,745, 2,052, 2,260, and
2,763 µg/g creatinine).
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